Log in to search using one of your social media accounts:

 

ACIP Recommends New Herpes Zoster Subunit Vaccine
The Advisory Committee on Immunization Practices is recommending preferential use of a new herpes zoster subunit (HZ/su; Shingrix) vaccine over currently available herpes zoster live (Zostavax) vaccine for adults ages 50 and older. (Source: AAFP News)
Source: AAFP News - October 31, 2017 Category: Primary Care Source Type: news

Shingrix (Zoster Vaccine Recombinant, Adjuvanted Suspension for Intramuscular Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 30, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Approves New Shingles Vaccine That Is More Than 90% Effective
BOSTON (CBS) – There’s a new shingles vaccine in town. Shingrix was approved by the FDA last week, and a CDC advisory panel just voted to recommend it for patients 50 and older. It is given as two injections two to six months apart, and in studies the vaccine was found to be more than 90% effective. Shingrix is not the only shingles vaccine available. Zostavax has been around for more than a decade, but it may not be as effective as this new vaccine, especially in older patients. Vaccine experts are not only recommending the new vaccine for people who have never been vaccinated but say that people who got the ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - October 26, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Syndicated Local Dr. Mallika Marshall Shingles Source Type: news

CDC Advisers Recommend New Herpes Zoster Vaccine over Zostavax (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM The CDC's Advisory Committee on Immunization Practices voted on Wednesday to recommend use of the newly approved herpes zoster vaccine, Shingrix.The inactivated, recombinant subunit, two-dosevaccine … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 26, 2017 Category: Primary Care Source Type: news

CDC Advisers Recommend New Herpes Zoster Vaccine over Zostavax (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM The CDC's Advisory Committee on Immunization Practices voted on Wednesday to recommend use of the newly approved herpes zoster vaccine, Shingrix.The non-live, recombinant subunit, two-dosevaccine … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 26, 2017 Category: Primary Care Source Type: news

ACIP Narrowly Recommends Shingrix for Shingles Over Zostavax ACIP Narrowly Recommends Shingrix for Shingles Over Zostavax
As a whole, the CDC panel is sold on the new recombinant vaccine to prevent herpes zoster, but some members want more safety data before they endorse it over Zostavax.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 25, 2017 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

C.D.C. Panel Recommends a New Shingles Vaccine
Shingrix is considered much more effective than the older vaccine, Zostavax. Health officials urged consumers over age 50 to be vaccinated. (Source: NYT Health)
Source: NYT Health - October 25, 2017 Category: Consumer Health News Authors: SHEILA KAPLAN Tags: Shingles (Disease) Vaccination and Immunization Advisory Committee on Immunization Practices Centers for Disease Control and Prevention Source Type: news

U.S. committee recommends GSK shingles vaccine over Merck rival
LONDON (Reuters) - The committee responsible for U.S. vaccination schedules has given a preferential recommendation to GlaxoSmithKline's newly approved shingles vaccine Shingrix over Merck& Co's established product Zostavax. (Source: Reuters: Health)
Source: Reuters: Health - October 25, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves New Herpes Zoster Vaccine (FREE)
By the Editors The FDA has approved a second vaccine to prevent herpes zoster in adults aged 50 and older, the manufacturer announced on Friday. … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 23, 2017 Category: Primary Care Source Type: news

Shingrix (zoster vaccine recombinant, adjuvanted) Approved in the U.S. for Prevention of Shingles
London UK 20 October 2017 -- GlaxoSmithKline plc [LSE/NYSE: GSK] today announced that the US Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 20, 2017 Category: Drugs & Pharmacology Source Type: news

GSK ’s Shingrix receives approval in Canada to prevent shingles
GlaxoSmithKline ’s (GSK) non-live, recombinant sub-unit, adjuvanted vaccine Shingrix has received approval from Health Canada to prevent shingles (herpes zoster) in people aged 50 or older. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 15, 2017 Category: Pharmaceuticals Source Type: news

Most Popular NEJM Group Feature This Week: New Zoster Vaccine Worth Waiting For (FREE)
By the Editors Here's the most clicked-on item we featured from NEJM … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 22, 2017 Category: Primary Care Source Type: news

From the Blogs: New Zoster Vaccine Worth Waiting For / Benefits & Risks of Curbside Consults (FREE)
By the Editors Take a look at what the NEJM Journal Watch bloggers are talking … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 18, 2017 Category: Primary Care Source Type: news

FDA Advisers Recommend Approval of New Shingles Vaccine (FREE)
By the Editors An FDA advisory panel voted 11-0 on Wednesday in favor of approving the Shingrix herpes zoster vaccine for adults … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 14, 2017 Category: Primary Care Source Type: news

US FDA advisory committee votes for GSK ’s Shingrix to prevent shingles
The US Food and Drug Administration ’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) has voted unanimously for GlaxoSmithKline’s (GSK) Shingrix (HZ/su) to prevent herpes zoster (shingles) in adults of 50 years of age and a… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 13, 2017 Category: Pharmaceuticals Source Type: news

FDA Panel Recommends New Shingles Vaccine FDA Panel Recommends New Shingles Vaccine
An FDA panel unanimously recommended zoster vaccine recombinant (adjuvanted) (Shingrix, GlaxoSmithKline) for adults aged 50 years and older.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2017 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

FDA Advisory Committee Votes Unanimously for Shingrix (HZ/su) in the US for Prevention of Herpes Zoster (Shingles) in Adults Ages 50 and Over
London UK 13 September 2017 -- GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US Food and Drug Administration (FDA) voted unanimously that the data support the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - September 13, 2017 Category: Drugs & Pharmacology Source Type: news

Tofacitinib After Live Shingles Vaccination Does Not Impair Immunogenicity Tofacitinib After Live Shingles Vaccination Does Not Impair Immunogenicity
Tofacitinib begun 2 to 3 weeks after live zoster vaccination does not impair immunogenicity, and vaccination appears to be safe in patients with pre-existing varicella-zoster virus (VZV) immunity, researchers report.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 31, 2017 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

New Herpes Zoster Vaccine Close to FDA Approval
A new recombinant adjuvanted herpes zoster vaccine awaiting potential approval from the Food and Drug Administration has been shown to have close to 90% efficacy at 4 years among research participants older than 70 and even those older than 80. (Source: Caring for the Ages)
Source: Caring for the Ages - August 30, 2017 Category: Health Management Authors: Christine Kilgore Source Type: news

Shingles Vax Effective in RA Patients onJAK Inhibitor (CME/CE)
(MedPage Today) -- Study directly assessed safety, immunogenicity of live zoster vaccine (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - August 29, 2017 Category: Rheumatology Source Type: news

Shingles Vax Effective in RA Patients on JAK Inhibitor (CME/CE)
(MedPage Today) -- Study directly assessed safety, immunogenicity of live zoster vaccine (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 29, 2017 Category: Primary Care Source Type: news

Doctors urge shingles vaccine to be used in arthritis patients
Researchers at Oregon Health and Science University found that the live varicella-zoster, or shingles, vaccine boosts the immune response in arthritis patients. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 28, 2017 Category: Consumer Health News Source Type: news

Studies reveal how shingles vaccine should be used in arthritis patients
(Wiley) New research indicates that the live varicella-zoster vaccine -- which is given to protect against shingles -- elicits robust immune responses in patients when administered several weeks prior to the start of treatment with the arthritis drug tofacitinib. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 28, 2017 Category: International Medicine & Public Health Source Type: news

Notes from the Field: Hospital Contact Investigation for a Patient Who Developed a Zoster Vaccine –Related Rash — Maryland, February 2015
(Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - July 20, 2017 Category: American Health Source Type: news

Shingles Vaccination: Why Wait?
ACIP recommends the zoster vaccine be given at age 60 years. That could be too late for some. And, what about this 60-year-old? (Source: ConsultantLive)
Source: ConsultantLive - July 14, 2017 Category: Internal Medicine Authors: Terry Brenneman, MD Tags: Vaccines Source Type: news

Analysis Strengthens Herpes Zoster Link With Stroke, MI Analysis Strengthens Herpes Zoster Link With Stroke, MI
More research is needed to elucidate the effect of antiviral-agent use or vaccination on cardiovascular outcomes after herpes zoster infection, the authors said.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 11, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

I Got Shingles As A Healthy 34-Year-Old, And It Was The Worst Pain I've Ever Felt
By Amanda MacMillan A few weeks after my 34th birthday, my husband and I went for a Saturday hike — a weekly ritual we’d started after moving to New York State’s Catskill Mountains region a few months earlier. I’d been feeling a bit under the weather, and I hoped the fresh autumn air would do me good. It didn’t. Later that night, I had chills and my skin felt strangely sensitive, like when you’re coming down with the flu. On top of that, it felt like I had pulled a muscle in my back or chest; when I breathed or stretched certain ways, I’d get shooting pains across my body. I blamed...
Source: Healthy Living - The Huffington Post - May 4, 2017 Category: Consumer Health News Source Type: news

Thousands damaged by shingles vaccine are trying to sue Merck
(Natural News) What was supposed to be a cure for shingles has brought on worse complications. Thousands have attempted to file lawsuits against American pharmaceutical company Merck & Co. for problems associated with their product Zostavax. In an interview with TROFire.com, Troy Bouk, Associate Attorney at the Levin Papantonio law firm, stated that the side... (Source: NaturalNews.com)
Source: NaturalNews.com - April 27, 2017 Category: Consumer Health News Source Type: news

AAFP: Educational Videos Created to Boost Adult Vaccine Uptake
New videos focus on influenza, zoster, and pneumococcal vaccine uptake among adults (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 15, 2017 Category: Respiratory Medicine Tags: Family Medicine, Geriatrics, Infections, Internal Medicine, Nursing, Pharmacy, Pulmonology, Institutional, Source Type: news

Zostavax
(Source: What's New at CBER)
Source: What's New at CBER - March 16, 2017 Category: Biomedical Science Source Type: news

In First Phase 3 Trial, Merck ’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first Phase 3 study results for V212, the company ’s investigational inactivated varicella zoster virus vaccine (VZV) for the prevention of herpes zoster or HZ, also known as shingles, in immunocompromised patients.Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orSkip Irvine, 267-305-0338orInvestors:Amy Klug, 908-740-1898orMichael DeCarbo, 908-740-1807Ticker Slug:Ticker:MRKExchange:NYSE @Merckread more (Source: Merck.c...
Source: Merck.com - Research and Development News - February 24, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news

Why Skipping Vaccines Is A Public, Not Personal, Health Choice
(Reuters Health) - Too many U.S. adults are not getting vaccinated, putting themselves and others at risk, immunization experts say. According to the latest available data, about 44 percent of adults over age 19 had a flu shot; 20 percent had a TDAP vaccine, which protects against tetanus, diphtheria and pertussis; and 20 percent of 19-to-64-year-olds at risk of pneumonia had that vaccine (compared to 60 percent of those over 65). Just 27 percent of those over age 60 were vaccinated against herpes zoster, which cuts the risk of shingles in half, according to new guidelines from the Advisory Committee on Immunization P...
Source: Science - The Huffington Post - February 8, 2017 Category: Science Source Type: news

Scientists shocked to learn that shingles vaccines can transform vaccinated people into "carriers" who spread infectious disease
(Natural News) Shingles, also known as “zoster” or “herpes zoster,” will affect roughly 1 out of every 3 American adults during their lifetime. Estimates suggest that there are upwards of one million cases of shingles each year in the United States. The disease is caused by dormant varicella zoster virus — the same virus that... (Source: NaturalNews.com)
Source: NaturalNews.com - January 23, 2017 Category: Consumer Health News Source Type: news

Herpes zoster (shingles) immunisation programme 2015 to 2016: evaluation report
This report is an evaluation of the third year of the shingles vaccination programme. It highlights the lower coverage achieved in the routine and catch-up cohort in 2015-16 compared with previous years. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 2, 2016 Category: Consumer Health News Source Type: news

GSK Announces EU Regulatory Submission of Candidate Vaccine for Prevention of Shingles
GlaxoSmithKline plc (LSE/NYSE: GSK) has announced the regulatory submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval for its candidate shingles vaccine, ShingrixTM, for the prevention of herpes zoster (shingles) in people aged 50 years or over. (Source: World Pharma News)
Source: World Pharma News - November 28, 2016 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

Shingles vaccination not at goal levels for U.S. seniors
(Reuters Health) – Just one in five people over age 60 in the U.S. have been vaccinated against a painful eruption of herpes zoster, also known as shingles, despite recommendations that all of them should get the shot. (Source: Reuters: Health)
Source: Reuters: Health - November 24, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Recombinant Zoster Vaccine Works Well in Older Patients (FREE)
By Abigail Zuger, MD Dr. Zuger is an associate editor with NEJM Journal Watch General Medicine, from which this story was adapted. Full coverage is available to subscribers at the link below.A new two-dose recombinant zoster vaccine was 90% efficacious among adults older than 70 in an industry-supported, randomized trial published in the New … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 14, 2016 Category: Primary Care Source Type: news

Investigational zoster vaccine effective, safe after age 70
The herpes zoster subunit vaccine was effective and safe for adults aged 70 and older in a phase III manufacturer-sponsored clinical trial, which was reported online in the New England Journal of Medicine. The ZOE-70 study (Zoster Efficacy Study in Adults 70 years of Age or Older) assessed an... (Source: Skin and Allergy News)
Source: Skin and Allergy News - September 14, 2016 Category: Dermatology Source Type: news

Chickenpox Cases Down 85 Percent Since 2-Dose Vaccine Started: CDC
THURSDAY, Sept. 1, 2016 -- Chickenpox -- which is caused by the varicella-zoster virus -- has continued declining in the United States since 2006, when doctors began routinely recommending a second dose of chickenpox (varicella) vaccine, U.S. health... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 1, 2016 Category: Journals (General) Source Type: news

Varicella Zoster Virus Infection in Neonates
Varicella zoster virus (VZV) can cause a spectrum of clinical manifestations in the fetus and neonate, which range from a self-limited exanthema to congenital malformations and/or death. Once a ubiquitous virus in the community, the epidemiology of VZV has dramatically changed in countries that have introduced the varicella vaccine into their routine immunization schedule. Practitioners must be cautioned against complacency with this virus, however, because unrecognized infection can have far-reaching consequences for the expectant mother, fetus, and neonate. VZV should be included in the differential diagnosis of patients...
Source: NeoReviews recent issues - August 31, 2016 Category: Pediatrics Authors: Petersen, R., Miller, A. S. Tags: Pediatric Drug Labeling Update Articles Source Type: news

Zoster Vaccine Quiz: How are We Doing?
We are 10 years into the Zostavax life cycle. Find out how the shingles vaccine is performing and what you know about it. (Source: ConsultantLive)
Source: ConsultantLive - July 14, 2016 Category: Internal Medicine Authors: Terry Brenneman, MD Tags: Vaccines Source Type: news

Could Zostavax use a Booster?
Who gets the best protection from Zostavax and how long does it last? Is that enough? (Source: ConsultantLive)
Source: ConsultantLive - July 14, 2016 Category: Internal Medicine Authors: Terry Brenneman, MD Tags: Vaccines Source Type: news

Intradermal Varicella-Zoster Vaccine Elicits Greater Antibody ResponseIntradermal Varicella-Zoster Vaccine Elicits Greater Antibody Response
Intradermal administration of varicella-zoster virus vaccine elicits a greater antibody response in older adults than does subcutaneous administration at comparable doses, researchers have reported. Reuters Health Information (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - April 28, 2016 Category: Infectious Diseases Tags: Public Health & Prevention News Source Type: news

Vaccines for preventing herpes zoster in older adults - new Cochrane Review
The review concludes that Herpes zoster vaccine is effective in preventing herpes zoster disease, and this protection can last three years. In general, zoster vaccine is well tolerated; it produces few systemic adverse events and injection site adverse events of mild to moderate intensity.There are studies of a new vaccine (with a VZV glycoproteic fraction plus adjuvant), which is currently not yet available for clinical use. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 5, 2016 Category: Consumer Health News Source Type: news

Featured Review: Vaccines for preventing herpes zoster in older adults
Vaccine helps prevent shingles in older adults for up to three years The varicella zoster virus causes chickenpox and can remain dormant inside nerve cells. After many years, it can reactivate and travel through the nerve to the skin, causing itching, numbness, tingling or local pain, and then blisters along the nerve path. These blisters are often accompanied with inflammation of the nerves and severe pain, which can affect quality of life. This is called herpes zoster or shingles. It affects people with low immunity such as older people. There are about 5.22 episodes of shingles for every 1000 older people. This is ...
Source: Cochrane News and Events - March 21, 2016 Category: Information Technology Authors: mumoquit at cochrane.org Source Type: news

As varicella recedes, zoster rises: The question is ‘why?’
WASHINGTON – As the number of children vaccinated against varicella has risen, the number of chicken pox cases has proportionally declined. No news there. But, as the number of kids getting... (Source: Pediatric News)
Source: Pediatric News - March 13, 2016 Category: Journals (General) Source Type: news

Shingles: questions and answers for healthcare professionals
A universal routine herpes zoster (shingles) vaccination programme for adults aged over 70 years started in September 2013. (Source: NHS Networks)
Source: NHS Networks - February 25, 2016 Category: UK Health Source Type: news

Don’t shrug off shingles
If you had chickenpox as a kid, there is a good chance you may develop shingles later in life. “In fact, one in three is predicted to get shingles during their lifetime,” says Dr. Anne Louise Oaklander, director of the Nerve Unit at Harvard-affiliated Massachusetts General Hospital. The same varicella-zoster virus that causes chickenpox also causes shingles. After the telltale spots of chickenpox vanish, the virus lies dormant in your nerve cells near the spinal cord and brain. When your immunity weakens from normal aging or from illnesses or medications, the virus can re-emerge. It then travels along a nerve t...
Source: New Harvard Health Information - February 18, 2016 Category: Consumer Health News Authors: Matthew Solan Tags: Healthy Aging Infectious diseases Vaccines Source Type: news

Chickenpox, shingles vaccine may cause corneal inflammation in some patients
In use for more than 20 years, the varicella zoster virus vaccine for chickenpox and shingles is considered an essential medicine by the World Health Organization (WHO). However, researchers have found, in rare instances, a link between the vaccine and corneal inflammation. It is a finding the researchers say should be discussed by primary care physicians and patients with a history of eye inflammation before getting vaccinated. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 20, 2016 Category: Science Source Type: news

Chickenpox, shingles vaccine may cause corneal inflammation in some patients
(University of Missouri-Columbia) In use for more than 20 years, the varicella zoster virus vaccine for chickenpox and shingles is considered an essential medicine by the World Health Organization (WHO). However, researchers from the University of Missouri School of Medicine have found, in rare instances, a link between the vaccine and corneal inflammation. It is a finding the researchers say should be discussed by primary care physicians and patients with a history of eye inflammation before getting vaccinated. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 20, 2016 Category: Infectious Diseases Source Type: news